View downloadable slides from our live meeting series for clinicians who treat and manage patients with progressive non-small cell lung cancer (NSCLC). Get the latest updates on antiangiogenic and immunotherapeutic treatment options for patients with nononcogene-driven tumors.
Jul 27, 2018
Jul 27, 2019
- Antiangiogenic therapy after progression on first-line platinum-based therapy
- The rapidly evolving role of immunotherapy in advanced stage NSCLC
- Predictive biomarkers for checkpoint immunotherapy in advanced stage NSCLC
- How moving immunotherapy into the first-line setting impacts selection of second-line therapy
- Immune-related adverse events in NSCLC
This educational meeting series is designed for the healthcare team that treats and manages patients with lung cancer including: Medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, surgeons, nurses, nurse practitioners, physician assistants, and other healthcare professionals.
After successful completion of this educational activity, participants should be able to:
- Identify patient and disease characteristics to be considered during treatment decision making for patients with progressive NSCLC
- Assess second- and third-line treatment options for advanced squamous and nonsquamous NSCLC, including immunotherapy and antiangiogenic therapy
- Select the optimal sequence of therapy for individual patients with advanced NSCLC who progressed on platinum-based therapy and/or immunotherapy
This educational activity is supported by a grant from Lilly.
Enduring Materials From a Certified Activity
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity.
Dr Gandara has disclosed that he has received consulting fees from AstraZeneca and consulting and speaking and teaching fees from Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Wakelee has disclosed that she has received consulting fees from ACEA, Genentech, Helsinn, Peregrine, and Pfizer. She has also performed contracted research for or received research support from AstraZeneca/Medimmune, Bristol-Myers Squibb, Celgene, Clovis, Exelixis, Genentech/Roche, Gilead, Lilly, Novartis, Pfizer, Pharmacyclics, and Xcovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed:
- Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
- Kristin Tomlinson, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.